Abstract |
Retrospective analyses suggest a benefit of therapy with hypomethylating agents in patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who relapse after allogeneic hematopoietic cell transplantation (HCT). We conducted a prospective trial in 39 patients with MDS or AML who relapsed within 100 days of HCT. Relapse was documented by morphology, flow cytometry, or cytogenetics. Treatment consisted of 5-azacitidine, 75 mg/m2/day for 7 days, administered every 28 days. Patients were followed by sequential marrow examinations, and responses were assessed at 6 months. There were 3 complete remissions and 9 partial remissions (30%); an additional 3 patients had stable disease by International Working Group criteria. In multivariate analysis, only the type of induction chemotherapy given before HCT was significantly associated with post-HCT response to 5-azacitidine and overall survival (P = .004). These data support the use of hypomethylating therapy for post-HCT relapse in patients with MDS and AML and suggest that pre-HCT therapy may affect the likelihood of response to this salvage approach.
|
Authors | Janghee Woo, H Joachim Deeg, Barry Storer, Cecilia Yeung, Min Fang, Marco Mielcarek, Bart L Scott |
Journal | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
(Biol Blood Marrow Transplant)
Vol. 23
Issue 1
Pg. 176-179
(01 2017)
ISSN: 1523-6536 [Electronic] United States |
PMID | 27789363
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Antimetabolites, Antineoplastic
- Azacitidine
|
Topics |
- Adult
- Aged
- Antimetabolites, Antineoplastic
(therapeutic use)
- Azacitidine
(administration & dosage, therapeutic use)
- Female
- Hematopoietic Stem Cell Transplantation
(methods, mortality, standards)
- Humans
- Induction Chemotherapy
(methods)
- Leukemia, Myeloid, Acute
(mortality, therapy)
- Male
- Middle Aged
- Myelodysplastic Syndromes
(mortality, therapy)
- Recurrence
- Remission Induction
(methods)
- Survival Rate
|